GW&K Investment Management LLC Sells 16,620 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

GW&K Investment Management LLC lowered its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 0.9% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,745,641 shares of the biopharmaceutical company’s stock after selling 16,620 shares during the quarter. Halozyme Therapeutics makes up approximately 0.7% of GW&K Investment Management LLC’s holdings, making the stock its 27th biggest holding. GW&K Investment Management LLC owned about 1.37% of Halozyme Therapeutics worth $83,459,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in HALO. Geode Capital Management LLC lifted its position in shares of Halozyme Therapeutics by 1.0% during the third quarter. Geode Capital Management LLC now owns 3,060,131 shares of the biopharmaceutical company’s stock worth $175,194,000 after purchasing an additional 30,901 shares in the last quarter. Congress Asset Management Co. raised its position in Halozyme Therapeutics by 446.5% in the 3rd quarter. Congress Asset Management Co. now owns 2,433,579 shares of the biopharmaceutical company’s stock worth $139,298,000 after purchasing an additional 1,988,238 shares during the last quarter. Boston Trust Walden Corp raised its position in Halozyme Therapeutics by 28.0% in the 4th quarter. Boston Trust Walden Corp now owns 874,081 shares of the biopharmaceutical company’s stock worth $41,790,000 after purchasing an additional 191,465 shares during the last quarter. Janus Henderson Group PLC lifted its holdings in Halozyme Therapeutics by 6.2% during the 3rd quarter. Janus Henderson Group PLC now owns 545,173 shares of the biopharmaceutical company’s stock worth $31,204,000 after buying an additional 31,871 shares in the last quarter. Finally, Glenmede Trust Co. NA boosted its position in Halozyme Therapeutics by 28.9% in the 3rd quarter. Glenmede Trust Co. NA now owns 487,131 shares of the biopharmaceutical company’s stock valued at $27,883,000 after buying an additional 109,283 shares during the last quarter. Institutional investors own 97.79% of the company’s stock.

Analysts Set New Price Targets

HALO has been the subject of a number of recent research reports. Wells Fargo & Company dropped their target price on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a research report on Monday, January 13th. JMP Securities boosted their price objective on Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a “market outperform” rating in a report on Friday, November 1st. HC Wainwright raised their target price on shares of Halozyme Therapeutics from $70.00 to $72.00 and gave the company a “buy” rating in a research note on Wednesday, February 19th. Benchmark reiterated a “buy” rating and set a $75.00 price target on shares of Halozyme Therapeutics in a research report on Thursday, February 20th. Finally, Piper Sandler increased their price objective on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the company a “neutral” rating in a report on Friday, January 10th. Four research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $62.78.

Insider Buying and Selling

In other news, SVP Michael J. Labarre sold 1,697 shares of the company’s stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $58.28, for a total value of $98,901.16. Following the completion of the transaction, the senior vice president now owns 173,756 shares in the company, valued at $10,126,499.68. This represents a 0.97 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Jeffrey William Henderson sold 5,000 shares of the stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $56.30, for a total transaction of $281,500.00. Following the sale, the director now directly owns 38,611 shares of the company’s stock, valued at $2,173,799.30. This represents a 11.46 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 26,697 shares of company stock valued at $1,461,001. 2.40% of the stock is owned by corporate insiders.

Halozyme Therapeutics Stock Down 0.4 %

Halozyme Therapeutics stock opened at $57.70 on Friday. Halozyme Therapeutics, Inc. has a fifty-two week low of $37.73 and a fifty-two week high of $65.53. The company has a debt-to-equity ratio of 4.14, a current ratio of 7.80 and a quick ratio of 9.15. The firm has a market capitalization of $7.11 billion, a price-to-earnings ratio of 16.82, a PEG ratio of 0.42 and a beta of 1.25. The company’s 50 day simple moving average is $54.08 and its 200 day simple moving average is $54.71.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share for the quarter, topping analysts’ consensus estimates of $1.17 by $0.02. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. The company had revenue of $298.01 million for the quarter, compared to analysts’ expectations of $285.74 million. As a group, sell-side analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.